Diabetes Core Update Podcasts

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study. Beernink et al. Diabetes Care 2023;46(3):602-607. https://doi.org/10.2337/dc22-1514.

An Examination of Whether Diabetes Control and Treatments Are Associated With Change in Frailty Index Across 8 Years: An Ancillary Exploratory Study From the Action for Health in Diabetes (Look AHEAD) Trial. Simpson et al. Diabetes Care 2023;46(3):519-525. https://doi.org/10.2337/dc22-1728.

Semaglutide Improves Cardiometabolic Risk Factors in Adults With Overweight or Obesity: STEP 1 and 4 Exploratory Analyses. Kosiborod et al. Diabetes Obes Metab 2023;25(2):468-478. https://doi.org/10.1111/dom.14890.

Glucagon Prescribing and Costs Among U.S. Adults With Diabetes, 2011–2021. Herges et al. Diabetes Care 2023;46(3):620-627. https://doi.org/10.2337/dc22-1564..

Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders. Rigby et al. Diabetes Care 2023;46(3):561–569. https://doi.org/10.2337/dc22-0908.

Youth-Onset Type 2 Diabetes: The Epidemiology of an Awakening Epidemic. Perng et al. Diabetes Care 2023;46(3):490-499. https://doi.org/10.2337/dci22-0046.

Dietary Factors and All-Cause Mortality in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Prospective Observational Studies. Barbaresko et al. Diabetes Care 2023;46(2):469-477. https://doi.org/10.2337/dc22-1018.

Prevalence and Predictors of Household Food Insecurity and Supplemental Nutrition Assistance Program Use in Youth and Young Adults With Diabetes: The SEARCH for Diabetes in Youth Study. Malik et al. Diabetes Care 2023;46(2):278-285. https://doi.org/10.2337/dc21-0790.

Association of Sodium–Glucose Cotransporter 2 Inhibitors With Time to Dementia: A Population-Based Cohort Study. Wu et al. Diabetes Care 2023;46(2):297-304. https://doi.org/10.2337/dc22-1705.

Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. Dimakos et al. Diabetes Care 2023;46(2):377-383. https://doi.org/10.2337/dc22-1584.

LY3437943, A Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People With Type 2 Diabetes: A Phase 1b, Multicentre, Double-Blind, Placebo-Controlled, Randomised, Multiple-Ascending Dose Trial. Urva et al. Lancet 2022;400(10366):1869-1881. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02033-5/fulltext.

Different Types of Industry-Produced and Ruminant Trans Fatty Acid Intake and Risk of Type 2 Diabetes: Findings From the NutriNet-Santé Prospective Cohort. Wendeu-Foyet et al. Diabetes Care 2023;46(2):321-330. https://doi.org/10.2337/dc22-0900.

Long-term Weight Training and Mortality in U.S. Male Health Professionals With and Without Type 2 Diabetes. Lee et al. Diabetes Care 2023;46(1):138–148. https://doi.org/10.2337/dc21-2420.

Trajectories of Cognition and Daily Functioning Before and After Incident Diabetes. Ji et al. Diabetes Care 2023;46(1):75–82. https://doi.org/10.2337/dc22-1190.

The Portfolio Diet and Incident Type 2 Diabetes: Findings From the Women's Health Initiative Prospective Cohort Study. Glenn et al. Diabetes Care 2023;46(1):28–37. https://doi.org/10.2337/dc22-1029.

Racial Disparities in Access and Use of Diabetes Technology Among Adult Patients With Type 1 Diabetes in a U.S. Academic Medical Center. Kanbour et al. Diabetes Care 2023;46(1):56–64. https://doi.org/10.2337/dc22-1055.

Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Cromer et al. Diabetes Care 2023;46(1):65–74. https://doi.org/10.2337/dc22-0383.

Sleep Duration and Risks of Incident Cardiovascular Disease and Mortality Among People With Type 2 Diabetes. Han et al. Diabetes Care 2023;46(1):101–110. https://doi.org/10.2337/dc22-1127.

Empagliflozin in Patients with Chronic Kidney Disease. The EMPA-KIDNEY Collaborative Group. N Engl J Med November 4, 2022. https://doi.org/10.1056/NEJMoa2204233.

Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease. Lamprea-Montealegre et al. Diabetes Care 2022;45(12):2900–2906. https://doi.org/10.2337/dc22-0614.

Relationship Between Carbohydrate Intake (Quantity, Quality, and Time Eaten) and Mortality (Total, Cardiovascular, and Diabetes): Assessment of 2003–2014 National Health and Nutrition Examination Survey Participants. Hou et al. Diabetes Care 2022;45(12):3024–3031. https://doi.org/10.2337/dc22-0462.

Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). de Boer et al. Diabetes Care 2022;45(12):3075–3090. https://doi.org/10.2337/dci22-0027.

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium–Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis. Rossing et al. Diabetes Care 2022;45(12):2991–2998. https://doi.org/10.2337/dc22-0294.

Effects of a Low-Carbohydrate Dietary Intervention on Hemoglobin A1c: A Randomized Clinical Trial. Dorans et al. JAMA Netw Open 2022;5(10):e2238645. https://doi.org/10.1001/jamanetworkopen.2022.38645.

Effects Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. Solomon et al. N Engl J Med 2022;387(12):1089-1098. https://doi.org/10.1056/NEJMoa2206286.

Herpes Zoster Incidence and Burden in Adults With Type 2 Diabetes in the U.S.: A Retrospective Database Analysis. Poirrier et al. Diabetes Care 2022;45(11):2585–2593. https://doi.org/10.2337/dc21-2053.

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Heerspink et al. Lancet Diabetes Endocrinol 2022;10(11):774-785. https://doi.org/10.1016/S2213-8587(22)00243-1.

Productivity Loss and Medical Costs Associated With Type 2 Diabetes Among Employees Aged 18–64 Years With Large Employer-Sponsored Insurance. Park et al. Diabetes Care 2022;45(11):2553–2560. https://doi.org/10.2337/dc22-0445.

Initiation of New Glucose-Lowering Therapies May Act to Reduce Physical Activity Levels: Pooled Analysis From Three Randomized Trials. Yates et al. Diabetes Care 2022;45(11):2749–2752. https://doi.org/10.2337/dc22-0888.

Risk Factors for the Development of Retinopathy in Prediabetes and Type 2 Diabetes: The Diabetes Prevention Program Experience. White et al. Diabetes Care 2022;45(11):2653–2661. https://doi.org/10.2337/dc22-0860.

Effects of Patient-Driven Lifestyle Modification Using Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: Results From the Randomized Open-label PDF Study. Choe et al. Diabetes Care 2022;45(10):2224–2230. https://doi.org/10.2337/dc22-0764.

Trends in Prescribing Preferences for Antidiabetic Medications Among Patients With Type 2 Diabetes in the U.K. With and Without Chronic Kidney Disease, 2006–2020. Liaw et al. Diabetes Care 2022;45(10):2316–2325. https://doi.org/10.2337/dc22-0224.

Changes in Glucose Metabolism and Glycemic Status with Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants with Prediabetes in the STEP Program. Perreault et al. Diabetes Care 2022;45(10):2396–2405. https://doi.org/10.2337/dc21-1785.

Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline. Korytkowski at al. The Journal of Clinical Endocrinology & Metabolism 2022;107(8):2101–2128. https://academic.oup.com/jcem/article/107/8/2101/6605637.

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial. Mosenzon et al. Diabetes Care 2022;45(10):2350–2359. https://doi.org/10.2337/dc22-0382.

Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA_1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Purola et al. Diabetes Care 2022;45(10):2445–2448. https://doi.org/10.2337/dc21-2298.

Optimal Number of Steps per Day to Prevent All-Cause Mortality in People With Prediabetes and Diabetes. Cruz et al. Diabetes Care 2022;45(9):2156–2158. https://doi.org/10.2337/dc22-0524.

Undiagnosed Diabetes in U.S. Adults: Prevalence and Trends. Fang et al. Diabetes Care 2022;45(9):1994–2002. https://doi.org/10.2337/dc22-0242.

Twenty-Year Temporal Trends in Risk of Ischemic Stroke in Incident Type 2 Diabetes: A Danish Population-Based Cohort Study. Gyldenkerne et al. Diabetes Care 2022;45(9):2144–2151. https://doi.org/10.2337/dc22-0440.

The Gut Microbiome Composition Is Altered in Long-standing Type 1 Diabetes and Associates With Glycemic Control and Disease-Related Complications. Van Heck at al. Diabetes Care 2022;45(9):2084–2094. https://doi.org/10.2337/dc21-2225.

Association of Metabolic Syndrome With Incident Dementia: Role of Number and Age at Measurement of Components in a 28-Year Follow-up of the Whitehall II Cohort Study. Machado-Fragua et al. Diabetes Care 2022;45(9):2127–2135. https://doi.org/10.2337/dc22-0206.

Changes in Visual Impairment due to Diabetic Retinopathy During 1980–2019 Based on Nationwide Register Data. Purola et al. Diabetes Care 2022;45(9):2020–2027. https://doi.org/10.2337/dc21-2369.

Management and Outcomes of Severe Hypoglycemia Treated by Emergency Medical Services in the U.S. Upper Midwest. Myers et al. Diabetes Care 2022;45(8):1788–1798. https://doi.org/10.2337/dc21-1811.

Diabetes Microvascular Disease Diagnosis and Treatment After High-Deductible Health Plan Enrollment. Wharam et al. Diabetes Care 2022;45(8):1754–1761. https://doi.org/10.2337/dc21-2563.

Model for Integration of Monogenic Diabetes Diagnosis Into Routine Care: The Personalized Diabetes Medicine Program. Zhang et al. Diabetes Care 2022;45(8):1799–1806. https://doi.org/10.2337/dc21-1975.

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes Arslanian et al. NEJM June 4, 2022. DOI: 10.1056/NEJMoa2204601.

Dietary Protein Sources, Mediating Biomarkers, and Incidence of Type 2 Diabetes: Findings From the Women’s Health Initiative and the UK Biobank. Li et al. Diabetes Care 2022;45(8):1742–1753. https://doi.org/10.2337/dc22-0368.

Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Pop-Busui et al. Diabetes Care June 2022, Vol.45, 1670-1690. https://doi.org/10.2337/dci22-0014.

Early and ongoing stable glycaemic control is associated with a reduction in major adverse cardiovascular events in people with type 2 diabetes: A primary care cohort study. Whyte et al. Diabetes, Obesity and Metabolism, Volume 24, Issue 7, July 2022 https://doi.org/10.1111/dom.14705

Effect of Deintensifying Diabetes Medications on Negative Events in Older Veteran Nursing Home Residents Niznik et al. Diabetes Care May 2022, Vol.45, 1558-1567. https://doi.org/10.2337/dc21-2116.

Longitudinal Changes in Arterial Stiffness and Heart Rate Variability in Youth-Onset Type 1 Versus Type 2 Diabetes: The SEARCH for Diabetes in Youth Study. Shah et al. Diabetes Care June 2022, Vol.45, 1647-1656 https://doi.org/10.2337/dc21-2426.

Tirzepatide Once Weekly for the Treatment of Obesity Jastreboff et al. NEJM June 4, 2022. DOI: 10.1056/NEJMoa2206038.

Diabetes Remission in the Alliance of Randomized Trials of Medicine Versus Metabolic Surgery in Type 2 Diabetes (ARMMS-T2D). Kirwan et al. Diabetes Care March 2022, Vol.45, 1574-1583. https://doi.org/10.2337/dc21-2441.

Risks and burdens of incident diabetes in long COVID: a cohort study. Tie and Al-Aly. The Lancet VOLUME 10, ISSUE 5, P311-321, MAY 01, 2022. https://doi.org/10.1016/S2213-8587(22)00044-4.

Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults. Raghavan et al. Diabetes Care 2022;45(6):1335–1345. https://doi.org/10.2337/dc21-2492

Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials Tuttle et al. Diabetes Care 2022;45(6):1445–1452. https://doi.org/10.2337/dc21-2034.

Weight Change During the Postintervention Follow-up of Look AHEAD. Wing et al. Diabetes Care 2022;45(6):1306–1314. https://doi.org/10.2337/dc21-1990.

Progression to Diabetes Among Older Adults With Hemoglobin A1c–Defined Prediabetes in the US Koyama et al. JAMA Netw Open. 2022;5(4):e228158. 10.1001/jamanetworkopen.2022.8158.

Association Between Diabetes and Gray Matter Atrophy Patterns in a General Older Japanese Population: The Hisayama Study. Hirabayashi et al. Diabetes Care 2022;45(6):1364–1371. https://doi.org/10.2337/dc21-1911.

Changes in Physical Activity and the Risk of Dementia in Patients With New-Onset Type 2 Diabetes: A Nationwide Cohort Study. Yoo et al. Diabetes Care 2022;45(5):1091–1098. https://doi.org/10.2337/dc21-1597.

Trends in Prediabetes Among Youths in the US From 1999 Through 2018. Liu et al. AMA Pediatr. Published online March 28, 2022. doi:10.1001/jamapediatrics.2022.0077/

Adherence to the American Diabetes Association’s Glycemic Goals in the Treatment of Diabetes Among Older Americans, 2001–2018. Le et al. Diabetes Care 2022;45(5):1107–1115. https://doi.org/10.2337/dc21-1507.

Pregnancy Outcomes in Young Women With Youth-Onset Type 2 Diabetes Followed in the TODAY Study. TODAY Study Group. Diabetes Care 2022;45(5):1038–1045. https://doi.org/10.2337/dc21-1071.

Development and Progression of Diabetic Retinopathy in Adolescents and Young Adults With Type 2 Diabetes: Results From the TODAY Study. TODAY Study Group. Diabetes Care 2022;45(5):1049–1055. https://doi.org/10.2337/dc21-1072.

Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Look AHEAD Research Group. Diabetes Care 2022;45(5):1252–1259. https://doi.org/10.2337/dc21-1805.

The Incidence of Diabetes Among 2,777,768 Veterans With and Without Recent SARS-CoV-2 Infection. Wander et al. Diabetes Care 2022;45(4):782–788. https://doi.org/10.2337/dc21-1686.

Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes. Wright et al. Diabetes Care 2022;45(4):909–918. https://doi.org/10.2337/dc21-1113.

Persistence of Risk for Type 2 Diabetes After Gestational Diabetes Mellitus. Diaz-Santana et al. Diabetes Care 2022;45(4):864–870. https://doi.org/10.2337/dc21-1430.

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Rossing et al. Diabetes Care 2022;45(4):888–897. https://doi.org/10.2337/dc21-1944.

Use of Lipid-, Blood Pressure–, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. Nelson et al. JAMA. 2022;327(2):138-150. doi:10.1001/jamanetworkopen.2021.48030.

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
The SURPASS-5 Randomized Clinical Trial. Dahl et al. JAMA. 2022;327(6):534-545. doi:10.1001/jama.2022.0078.

The carbohydrate-insulin model: a physiological perspective on the obesity pandemic. Ludwig et al. The American Journal of Clinical Nutrition, Volume 114, Issue 6, December 2021, Pages 1873–1885. https://doi.org/10.1093/ajcn/nqab270.

Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study. Champakanath et al. Diabetes Care 2022;45(3):750–753. https://doi.org/10.2337/dc21-2004.

Type 2 Diabetes, Glycemic Control, and Their Association With Dementia and Its Major Subtypes: Findings From the Swedish National Diabetes Register. Celis-Morales et al. Diabetes Care 2022;45(3):634–641. https://doi.org/10.2337/dc21-0601.

Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience. Palanca et al. Diabetes Care 2022;45(3):650–658. https://doi.org/10.2337/dc21-1584.

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial. Rubino et al. JAMA. 2022;327(2):138-150. doi:10.1001/jama.2021.23619. doi:10.1001/jama.2021.23619.

Cost-Related Medication Nonadherence in Adults With Diabetes in the United States: The National Health Interview Survey 2013–2018. Taha et al. Diabetes Care 2022;45(3):594–603. https://doi.org/10.2337/dc21-1757.

Association of Bariatric Surgery With Cancer Incidence in Patients With Obesity and Diabetes: Long-term Results From the Swedish Obese Subjects Study. Sjöholm et al. Diabetes Care 2022;45(2):444–450. https://doi.org/10.2337/dc21-1335.

Universal Subsidized Continuous Glucose Monitoring Funding for Young People With Type 1 Diabetes: Uptake and Outcomes Over 2 Years, a Population-Based Study. Johnson et al. Diabetes Care 2022;45(2):391–397. https://doi.org/10.2337/dc21-1666.

Dietary Insulinemic Potential and Risk of Total and Cause-Specific Mortality in the Nurses’ Health Study and the Health Professionals Follow-up Study. Wan et al. Diabetes Care 2022;45(2):451–459. https://doi.org/10.2337/dc21-1530.

2022 National Standards for Diabetes Self-Management Education and Support. Davis et al. Diabetes Care 2022;45(2):484–494. https://doi.org/10.2337/dc21-2396.

Associations of Daily Steps and Step Intensity With Incident Diabetes in a Prospective Cohort Study of Older Women: The OPACH Study. Garduno et al. Diabetes Care 2022;45(2):339–347. https://doi.org/10.2337/dc21-1202.

Association of Statin Therapy Initiation With Diabetes Progression A Retrospective Matched-Cohort Study. Mansi et al. JAMA Intern Med. 2021;181(12):1562-1574. DOI: 10.1001/jamainternmed.2021.5714.

Remission of Type 2 Diabetes Following a Short-term Intensive Intervention With Insulin Glargine, Sitagliptin, and Metformin: Results of an Open-label Randomized Parallel-Design Trial. McInnes et al. Diabetes Care 2022;45(1):178–185. DOI: https://doi.org/10.2337/dc21-0278.

Gestational Diabetes Mellitus and the Risks of Overall and Type-Specific Cardiovascular Diseases: A Population- and Sibling-Matched Cohort Study. Yu et al. Diabetes Care 2022;45(1):151–159. https://doi.org/10.2337/dc21-1018.

Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. Agarwal et al. N Engl J Med 2021; 385:2507-2519. DOI: 10.1056/NEJMoa2110730.

Changes in the Prevalence of Symptoms of Depression, Loneliness, and Insomnia in U.S. Older Adults With Type 2 Diabetes During the COVID-19 Pandemic: The Look AHEAD Study. Chao et al. Diabetes Care 2022;45(1):74–82. https://doi.org/10.2337/dc21-1179.

Relationships of Changes in Physical Activity and Sedentary Behavior With Changes in Physical Fitness and Cardiometabolic Risk Profile in Individuals With Type 2 Diabetes: The Italian Diabetes and Exercise Study 2 (IDES_2). Pugliese et al. Diabetes Care 2022;45(1):213–221. https://doi.org/10.2337/dc21-1505.

Risk of Incident Dementia According to Glycemic Status and Comorbidities of Hyperglycemia: A Nationwide Population-Based Cohort Study. Lee et al. Diabetes Care 2022;45(1):134–141. https://doi.org/10.2337/dc21-0957.

The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. Aleppo et al. Diabetes Care 2021 Dec; 44(12): 2729-2737. DOI: https://doi.org/10.2337/dc21-1304.

Long-term Occupational Consequences for Families of Children With Type 1 Diabetes: The Mothers Take the Burden. Dehn-Hindenberg et al. Diabetes Care 2021 Dec; 44 (12): 2656-2663. https://doi.org/10.2337/dc21-0740.

Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Lee et al. Diabetes Care 2021 Dec; 44 (12): 2775-2782. https://doi.org/10.2337/dc21-1046.

Association of Sodium-Glucose Cotransporter–2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. Zhuo et al. JAMA Netw Open. 2021;4(10):e2130762. DOI:10.1001/jamanetworkopen.2021.30762.

Prediabetes Defined by First Measured HbA1c Predicts Higher Cardiovascular Risk Compared With HbA1c in the Diabetes Range: A Cohort Study of Nationwide Registries. Yahyavi et al. Diabetes Care 2021 Dec; 44 (12): 2767-2774. https://doi.org/10.2337/dc21-1062.

Trend of Diabetes-Related Hospital Admissions During the Transition Period From Adolescence to Adulthood in the State of California. Angel Siu Ying Nip and Maya Lodish. Diabetes Care 2021 Dec; 44 (12): 2723-2728. https://doi.org/10.2337/dc21-0555.

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. Pitt et al. N Engl J Med August 28, 2021. DOI: 10.1056/NEJMoa2110956.

Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Nagasu et al. Diabetes Care 2021 Nov; 44(11): 2542-2551. https://doi.org/10.2337/dc21-1081.

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Berg et al. Diabetes Care 2021 Nov; 44(11): 2573-2581. https://doi.org/10.2337/dc21-1170.

Empagliflozin in Heart Failure with a Preserved Ejection Fraction. Anker et al. N Engl J Med 2021; 385:1451-1461. DOI: 10.1056/NEJMoa2107038.

Patient-Centered Goal-Setting in the National Diabetes Prevention Program: A Pilot Study. Ritchie et al. Diabetes Care 2021 Nov; 44(11): 2464-2469. https://doi.org/10.2337/dc21-0677.

Association of Type 2 Diabetes, According to the Number of Risk Factors Within Target Range, With Structural Brain Abnormalities, Cognitive Performance, and Risk of Dementia. van Gennip et al. Diabetes Care 2021 Nov; 44(11): 2493-2502. https://doi.org/10.2337/dc21-0149.

Replacement of Sedentary Behavior by Various Daily-Life Physical Activities and Structured Exercises: Genetic Risk and Incident Type 2 Diabetes. Li et al. Diabetes Care 2021 Oct; 44(10): 2403-2410. https://doi.org/10.2337/dc21-0455.

Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort. den Braber et al. Diabetes Care 2021 Oct; 44(10): 2238-2244. https://doi.org/10.2337/dc20-2241.

Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. Harris et al. Diabetes Care 2021 Oct; 44(10): 2293-2301. https://doi.org/10.2337/dc21-0529.

Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. Lind et al. Diabetes Care 2021 Oct; 44(10): 2231-2237. https://doi.org/10.2337/dc20-2439.

Nationwide Trends in Cardiac Risk and Mortality in Patients With Incident Type 2 Diabetes: A Danish Cohort Study. Gyldenkerne et al. Diabetes Care 2021 Oct; 44(10): 2353-2360. https://doi.org/10.2337/dc21-0383.

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. Frías et al. N Engl J Med 2021; 385:503-515. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519.

Chronic Kidney Disease Testing Among Primary Care Patients With Type 2 Diabetes Across 24 U.S. Health Care Organizations. Stempniewicz et al. Diabetes Care 2021 Sep; 44(9): 2000-2009. https://doi.org/10.2337/dc20-2715.

Nutritional basis of type 2 diabetes remission. Taylor et al. BMJ 2021;374:n1449. https://doi.org/10.1136/bmj.n1449.

Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database. Alfego et al. Diabetes Care 2021 Sep; 44(9): 2025-2032. https://doi.org/10.2337/dc21-0723.

Preparing for the NASH Epidemic: A Call to Action. Kanwal et al. Diabetes Care 2021 Sep; 44(9): 2162-2172. https://doi.org/10.2337/dci21-0020.

Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic. Gregg et al. Diabetes Care 2021 Sep; 44(9): 1916-1923. https://doi.org/10.2337/dci21-0001.

High Out-of-pocket Health Care Cost Burden Among Medicare Beneficiaries With Diabetes, 1999–2017. Park et al. Diabetes Care 2021 Aug; 44(8): 1797-1804. https://doi.org/10.2337/dc20-2708.

Affect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. Martens T, Beck RW, Bailey R, et al. JAMA. 2021;325(22):2262–2272. doi:10.1001/jama.2021.7444.

Association of Real-time Continuous Glucose Monitoring With Glycemic Control and Acute Metabolic Events Among Patients With Insulin-Treated Diabetes. Karter AJ, Parker MM, Moffet HH, Gilliam LK, Dlott R. JAMA. 2021;325(22):2273–2284. doi:10.1001/jama.2021.6530.

Trends in Diabetes Treatment and Control in U.S. Adults, 1999–2018. Fang et al. N Engl J Med 2021; 384:2219-2228. DOI: 10.1056/NEJMsa2032271.

Weight Loss by Low-Calorie Diet Versus Gastric Bypass Surgery in People With Diabetes Results in Divergent Brain Activation Patterns: A Functional MRI Study. Salem et al. Diabetes Care 2021 Aug; 44(8): 1842-1851. https://doi.org/10.2337/dc20-2641.

The Women’s Leadership Gap in Diabetes: A Call for Equity and Excellence. Dunne et al. Diabetes Care 2021 Aug; 44(8): 1734-1743. https://doi.org/10.2337/dci21-0015.

The Women’s Leadership Gap in Diabetes: A Call for Equity and Excellence. Dunne et al. Diabetes 2021 Aug; 70(8): 1623-1633. https://doi.org/10.2337/db21-0052.

High Burden of Subclinical and Cardiovascular Disease Risk in Adults with Metabolically Healthy Obesity: The Atherosclerosis Risk in Communities (ARIC) Study. Commodore-Mensah et al. Diabetes Care 2021 Jul; 44 (7): 1657-1663. https://doi.org/10.2337/dc20-2227.

A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Lingvay et al. Diabetes Care 2021 Jul; 44(7): 1595-1603. https://doi.org/10.2337/dc20-2878.

Land Cover of Early-Life Environment Modulates the Risk of Type 1 Diabetes. Nurminen et al. Diabetes Care 2021 Jul; 44(7): 1506-1514. https://doi.org/10.2337/dc20-1719.

Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Bajaj et al. Diabetes Care 2021 Jul; 44(7): 1586-1594. https://doi.org/10.2337/dc20-2877.

Projecting the Incidence of Type 2 Diabetes–Related End-Stage Kidney Disease Until 2040: A Comparison Between the Effects of Diabetes Prevention and the Effects of Diabetes Treatment. Morton et al. Diabetes Care 2021 Jul; 44(7): 1515-1523. https://doi.org/10.2337/dc21-0220.

Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Walker et al. Diabetes Care 2021 Jul; 44(7): 1480-1490. https://doi.org/10.2337/dc20-2753.

Application of 2021 American Diabetes Association Glycemic Treatment Clinical Practice Recommendations in Primary Care. Colling et al. Diabetes Care 2021 June; 44(6): 1443-1446. https://doi.org/10.2337/dc21-0013.

Important Drop Rate of Acute Diabetes Complications in People With Type 1 or Type 2 Diabetes After Initiation of Flash Glucose Monitoring in France: The RELIEF Study. Roussel et al. Diabetes Care 2021 June; 44(6): 1368-1376. https://doi.org/10.2337/dc20-1690.

Frequency of Interruptions to Sitting Time: Benefits for Postprandial Metabolism in Type 2 Diabetes. Homer et al. Diabetes Care 2021 June; 44(6): 1254-1263. https://doi.org/10.2337/dc20-1410.

Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010–2016: An Analysis of More Than 25 Million Inhabitants. Claessen et al. Diabetes Care 2021 June; 44(6): 1291-1299. https://doi.org/10.2337/dc20-2477.

Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial. Giugliano et al. Diabetes Care 2021 June; 44(6): 1353-1360. https://doi.org/10.2337/dc20-2623.

Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials. Silverii et al. Diabetes Obes Metab. 2021; 23: 1052– 1056. https://doi.org/10.1111/dom.14286.

Body Weight Changes During Pandemic-Related Shelter-in-Place in a Longitudinal Cohort Study. Lin et al. JAMA Netw Open. 2021;4(3):e212536. doi:10.1001/jamanetworkopen.2021.2536.

Risk of Progression to Diabetes Among Older Adults With Prediabetes. Rooney et al. JAMA. JAMA Intern Med. 2021;181(4):511-519. doi:10.1001/jamainternmed.2020.8774.

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Cahn et al. Diabetes Care 2021 May; 44(5): 1159-1167. https://doi.org/10.2337/dc20-2492.

Associations of Diet Quality and All-Cause Mortality Across Levels of Cardiometabolic Health and Disease: A 7.6-Year Prospective Analysis From the Dutch Lifelines Cohort. Vinke et al. Diabetes Care 2021 May; 44(5): 1228-1235. https://doi.org/10.2337/dc20-2709.

Associations Between Exposure to Gestational Diabetes Mellitus In Utero and Daily Energy Intake, Brain Responses to Food Cues, and Adiposity in Children. Luo et al. Diabetes Care 2021 May; 44(5): 1185-1193. https://doi.org/10.2337/dc20-3006.

Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention. Bancks et al. Diabetes Care 2021 May; 44(5): 1203-1210. https://doi.org/10.2337/dc20-2372.

Once-Weekly Semaglutide in Adults with Overweight or Obesity. Wilding et al. N Engl J Med 2021; 384:989-1002. doi: 10.1056/NEJMoa2032183.

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial. Wadden TA, Bailey TS, Billings LK, et al. JAMA. Published online February 24, 2021. doi:10.1001/jama.2021.1831.

Glucose Control, Sulfonylureas, and Insulin Treatment in Elderly People With Type 2 Diabetes and Risk of Severe Hypoglycemia and Death: An Observational Study. Ling et al. Diabetes Care 2021 Apr; 44(4): 915-924. https://doi.org/10.2337/dc20-0876.

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. Persson et al. Diabetes Care 2021 Apr; 44(4): 1020-1026. https://doi.org/10.2337/dc20-1622.

Association of Metabolic Phenotypes With Coronary Artery Disease and Cardiovascular Events in Patients With Stable Chest Pain. Kammerlander et al. Diabetes Care 2021 Apr; 44(4): 1038-1045. https://doi.org/10.2337/dc20-1760.

Association of Objectively Measured Timing of Physical Activity Bouts With Cardiovascular Health in Type 2 Diabetes. Qian et al. Diabetes Care 2021 Apr; 44(4): 1046-1054. https://doi.org/10.2337/dc20-2178.

Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Dave et al. Circulation. 2021;143:770–779. https://doi.org/10.1161/CIRCULATIONAHA.120.047965.

Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Frias et al. Diabetes Care 2021 Mar; 44(3): 765-773. https://doi.org/10.2337/dc20-1473

The SEE Study: Safety, Efficacy, and Equity of Implementing Autonomous Artificial Intelligence for Diagnosing Diabetic Retinopathy in Youth. Wolf et al. Diabetes Care 2021 Mar; 44(3): 781-787. https://doi.org/10.2337/dc20-1671

Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology Collaboration on Occupational Health Study. Islam et al. Diabetes Care 2021 Mar; 44(3): 757-764. https://doi.org/10.2337/dc20-1213

Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study Blonde et al. Diabetes Care 2021 Mar; 44(3): 774-780. https://doi.org/10.2337/dc20-2023

Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Patorno et al. Diabetes Care 2021 Mar; 44(3): 826-835. https://doi.org/10.2337/dc20-1464

Changes in Plant-Based Diet Indices and Subsequent Risk of Type 2 Diabetes in Women and Men: Three U.S. Prospective Cohorts. Chen et al. Diabetes Care 2021 Mar; 44(3): 663-671. https://doi.org/10.2337/dc20-1636

Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study. Lu et al. Diabetes Care 2021 Feb; 44(2): 549-555. https://doi.org/10.2337/dc20-1862

Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Lomonaco et al. Diabetes Care 2021 Feb; 44(2): 399-406. https://doi.org/10.2337/dc20-1997

Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Abdul-Ghani et al. Diabetes Care 2021 Feb; 44(2): 433-439. https://doi.org/10.2337/dc20-0978

Glycemic Control and Risk of Cellulitis. Zacay et al. Diabetes Care 2021 Feb; 44(2): 367-372. https://doi.org/10.2337/dc19-1393

Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. Inzucchi et al. Diabetes Care 2021 Feb; 44(2): 586-594. https://doi.org/10.2337/dc20-1675

Association of Serum 25-Hydroxyvitamin D Concentrations With All-Cause and Cause-Specific Mortality Among Individuals With Diabetes. Wan et al. Diabetes Care 2021 Feb; 44(2): 350-357. https://doi.org/10.2337/dc20-1485

Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. Rosenstock et al. N Engl J Med 2020; 383:2107-2116. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2022474

The Impact of Bariatric Surgery on Incident Microvascular Complications in Patients With Type 2 Diabetes: A Matched Controlled Population-Based Retrospective Cohort Study. Singh et al. Diabetes Care 2021 Jan; 44(1): 116-124. https://doi.org/10.2337/dc20-0571

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. Bhatt et al. N Engl J Med November 16, 2020.DOI: 10.1056/NEJMoa2030186

Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015. Cheng et al. Diabetes Care 2021 Jan; 44(1): 89-97. https://doi.org/10.2337/dc20-1913

Sedentary Time and Metabolic Risk in Extremely Active Older Adults. Madden et al. Diabetes Care 2021 Jan; 44(1): 194-200. https://doi.org/10.2337/dc20-0849

Severe Hypoglycemia, Cardiac Structure and Function, and Risk of Cardiovascular Events Among Older Adults With Diabetes. Echouffo-Tcheugui et al. Diabetes Care 2021 Jan; 44(1): 248-254. https://doi.org/10.2337/dc20-0552